Nasal Spray for COVID-19 Also Protects Against Other Viruses | Digital Trends Spanish
A nasal spray developed by UK researchers to prevent the spread of COVID-19 has shown that it is also helpful in preventing infection with rhinovirus, the pathogen that causes the common cold.
In a study published in the European Respiratory Journal, Newcastle University researchers point out that the drug, known as INNA-X, showed effectiveness in preclinical studies in human airway cells.
Nathan Barlett, one of the signatories of the study, highlighted that the INNA-X nasal spray holds great promise for combating the spread of COVID-19 and other viral diseases, especially in those patients with conditions such as asthma, which complicate the treatment of respiratory infections.
“According to what we have reported for other respiratory viruses, including SARS-CoV-2 that causes COVID-19, treatment with INNA-X before infection reduced the viral load in the respiratory tract,” said the researcher. .
“We have examined the effect of INNA-X on the cells of the airways of patients with asthma, who we know have a lower antiviral immune response, and we found that the treatment with INNA-X was effective,” added the specialist.
The INNA-X drug is developed by the Australian biotechnology company Ena Respiratory. The spray works by stimulating the immune system of the respiratory tract, which is the body’s first line of defense against viruses that cause respiratory infections such as SARS-CoV-2 or rhinovirus.
For now, the drug remains in testing, and human clinical trials are expected to begin in the next few weeks. If successful, the drug could begin commercialization this year.